We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week
Published in Bladder Cancer

Journal Scan / Research · August 23, 2022

Outcomes of Maintenance Treatment With the Poly ADP–Ribose Polymerase Inhibitor Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma
J. Clin. Oncol 2022 Aug 12;[EPub Ahead of Print], SJ Crabb, S Hussain, E Soulis, S Hinsley, L Dempsey, A Trevethan, Y Song, J Barber, J Frew, J Gale, G Faust, S Brock, U McGovern, O Parikh, D Enting, S Sundar, G Ratnayake, K Lees, AJ Birtle, T Powles, RJ Jones

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading